Available forms
Drospirenone is available in the following formulations, brand names, and indications:
Drospirenone 4 mg (Slynd) – progestogen-only birth control pill
Drospirenone 3 mg and estetrol 14.2 mg (Nextstellis (US)) – combined birth control pill
Ethinylestradiol 30 μg and drospirenone 3 mg (Ocella, Syeda, Yasmin, Zarah, Zumandimine) – combined birth control pill
Ethinylestradiol 20 μg and drospirenone 3 mg (Gianvi,  Jasmiel, Loryna, Lo-Zumandimine, Nikki, Vestura, Yaz) – combined birth control pill, acne, PMS, PMDD, dysmenorrhea
Ethinylestradiol 30 μg, drospirenone 3 mg, and levomefolate calcium 0.451 mg (Beyaz, Tydemy) – combined birth control pill with vitamin B9 supplementation, acne, PMS
Estetrol 15 mg and drospirenone 3 mg (Nextstellis (CA)) – combined birth control pill
Estradiol 0.5 or 1 mg and drospirenone 0.25 or 0.5 mg (Angeliq) – menopausal hormone therapy (menopausal syndrome, postmenopausal osteoporosis)

Contraindications
Contraindications of drospirenone include renal impairment or chronic kidney disease, adrenal insufficiency, presence or history of cervical cancer or other progestogen-sensitive cancers, benign or malignant liver tumors or hepatic impairment, undiagnosed abnormal uterine bleeding, and hyperkalemia (high potassium levels). Renal impairment, hepatic impairment, and adrenal insufficiency are contraindicated because they increase exposure to drospirenone and/or increase the risk of hyperkalemia with drospirenone. Side effects
Adverse effects of drospirenone alone occurring in more than 1% of women may include unscheduled menstrual bleeding (breakthrough or intracyclic) (40.3–64.4%), acne (3.8%), metrorrhagia (2.8%), headache (2.7%), breast pain (2.2%), weight gain (1.9%), dysmenorrhea (1.9%), nausea (1.8%), vaginal hemorrhage (1.7%), decreased libido (1.3%), breast tenderness (1.2%), and irregular menstruation (1.2%).
Dermatitis herpetiformis (DH) is a chronic autoimmune blistering skin condition, characterised by intensely itchy blisters filled with a watery fluid. DH is a cutaneous manifestation of coeliac disease, although the exact causal mechanism is not known. DH is neither related to nor caused by herpes virus; the name means that it is a skin inflammation having an appearance (Latin: -formis) similar to herpes. The age of onset is usually about 15–40, but DH also may affect children and the elderly. Men are slightly more affected than women. Estimates of DH prevalence vary from 1 in 400 to 1 in 10,000. It is most common in patients of northern European and northern Indian ancestry, and is associated with the human leukocyte antigen (HLA) haplotype HLA-DQ2 or HLA-DQ8 along with coeliac disease and gluten sensitivity.Dermatitis herpetiformis was first described by Louis Adolphus Duhring in 1884. A connection between DH and coeliac disease was recognized in 1967. Signs and symptoms
Dermatitis herpetiformis is characterized by intensely itchy, chronic papulovesicular eruptions, usually distributed symmetrically on extensor surfaces (buttocks, back of neck, scalp, elbows, knees, back, hairline, groin, or face). : 616   The blisters vary in size from very small up to 1 cm across. The condition is extremely itchy, and the desire to scratch may be overwhelming. This sometimes causes the affected person to scratch the blisters off before they are examined by a physician.